Article
Hypoxia-induced shift in the phenotype of proteasome from 26S toward immunoproteasome triggers loss of immunoprivilege of mesenchymal stem cells.
Cell death & disease - 4 Jun 2020
Abu-El-Rub Ejlal, Sareen Niketa, Yan Weiang, Alagarsamy Keshav Narayan, Rafieerad Alireza, Srivastava Abhay, Desiderio Vincenzo, Dhingra Sanjiv
Abstract excerpt
Allogeneic mesenchymal stem cells (MSCs) are immunoprivileged and are being investigated in phase I and phase II clinical trials to treat different degenerative and autoimmune diseases. In spite of encouraging outcome of initial trials, the long-term poor survival of transplanted cells in the host tissue has declined the overall enthusiasm. Recent analyses of allogeneic MSCs based studies confirm that after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
